Improving fibrinolysis in venous thromboembolism: impact of fibrin structure
Authors:
- 5 July 2019
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 12 (8) , 597-607
Abstract
Introduction. Fibrinolysis is of key importance in maintaining vessel patency. Impaired fibrinolysis associated with more compact fibrin structure has been shown in patients with venous thromboembolism (VTE), including deep-vein thrombosis and pulmonary embolism (PE). Currently recombinant or modified plasminogen activators are the only commonly available thrombolytic agents. However, they are fraught with side effects and suboptimal effectiveness. Areas covered. Based on the available literature, the current evidence linking fibrinolysis with VTE and potential therapeutic targets among fibrinolysis proteins are presented. Expert opinion. Prolonged clot lysis time has been reported as a new predictor of first-time and recurrent VTE, including PE. Anticoagulant therapy, including non-vitamin K antagonist oral anticoagulants, has a favorable impact on fibrinolysis in VTE patients. Several VTE risk factors are also related to lower efficiency of fibrinolysis and their treatment improves fibrinolysis, in part by alterations to fibrin properties. There is an increasing number of studies aiming at developing novel profibrinolytic therapeutic agents for treatment of VTE patients, mostly targeting the antifibrinolytic proteins, i.e. antiplasmin, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.Keywords
Funding Information
- Jagiellonian University Medical College (K/ZDS/007717)
This publication has 93 references indexed in Scilit:
- Mechanisms of fibrin polymerization and clinical implicationsBlood, 2013
- Mechanical Stability and Fibrinolytic Resistance of Clots Containing Fibrin, DNA, and HistonesJournal of Biological Chemistry, 2013
- Architecture of fibrin network inside thrombotic material obtained from the right atrium and pulmonary arteries: flow and location matterJournal of Thrombosis and Thrombolysis, 2012
- Antithrombin-Independent Effects of Heparins on Fibrin Clot NanostructureArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Molecular Mechanisms Affecting Fibrin Structure and StabilityArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1Blood, 2010
- Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin‐activatable fibrinolysis inhibitorJournal of Thrombosis and Haemostasis, 2010
- High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertensionBlood, 2009
- New insights into the molecular mechanisms of the fibrinolytic systemJournal of Thrombosis and Haemostasis, 2009
- Synergistic Effects of Hypofibrinolysis and Genetic and Acquired Risk Factors on the Risk of a First Venous ThrombosisPLOS Medicine, 2008